<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40404681</article-id><article-id pub-id-type="pmc">PMC12098777</article-id>
<article-id pub-id-type="publisher-id">1899</article-id><article-id pub-id-type="doi">10.1038/s41598-025-01899-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Huaxian formula alleviates nickel oxide nanoparticle-induced pulmonary fibrosis via PI3K/AKT signaling</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Minmin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Liruohan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Mi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Xiaodong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bu</surname><given-names>Shi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jianfeng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Jingyu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Yujie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hou</surname><given-names>Ling</given-names></name><address><email>hlbelief@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Guanghua</given-names></name><address><email>ghlee0404@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02h8a1848</institution-id><institution-id institution-id-type="GRID">grid.412194.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 9803</institution-id><institution>School of Public Health, </institution><institution>Ningxia Medical University, </institution></institution-wrap>Yinchuan, 750004 Ningxia China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021r98132</institution-id><institution-id institution-id-type="GRID">grid.449637.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 966X</institution-id><institution>School of Public Health, </institution><institution>Shaanxi University of Chinese Medicine, </institution></institution-wrap>Xianyang, 712046 Shaanxi China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02h8a1848</institution-id><institution-id institution-id-type="GRID">grid.412194.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 9803</institution-id><institution>School of Basic Medicine, </institution><institution>Ningxia Medical University, </institution></institution-wrap>Yinchuan, 750004 Ningxia China </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>17862</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">As a progressive fibrotic lung disorder with high mortality, pulmonary fibrosis (PF) suffers from inadequate treatment options. While the traditional Chinese medicine (TCM) formulation Huaxian Formula (HXF) demonstrates multi-target therapeutic potential against PF, the identity of its active components and their mechanistic basis of action require systematic investigation. To elucidate the therapeutic effects and pharmacological mechanisms of HXF in treating PF induced by nickel oxide nanoparticles (nano NiO), utilizing network pharmacology (NP), molecular docking, as well as in vivo and in vitro experiments. A comprehensive analysis of authoritative databases identified 121 active compounds, 202 potential therapeutic targets, and 1664 PF-related genes. Among these, 105 overlapping targets were found between HXF and PF. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses identified the PI3K/AKT signaling pathway as both a pivotal mechanism in PF pathogenesis and a primary target of HXF&#x02019;s therapeutic effects. Molecular docking studies revealed that the six core compounds (quercetin, luteolin, kaempferol, &#x003b2;-sitosterol, isorhamnetin, and formononetin) of HXF exhibited strong binding affinity to proteins involved in the PI3K/AKT pathway. In the rat and A549 cell model, HXF treatment reduced collagen deposition and downregulated the expression of type I collagen (Col-I). Mechanistically, HXF inhibited the phosphorylation of PI3K and AKT. Collectively, these findings suggested that HXF alleviated PF by modulating the PI3K/AKT signaling pathway, providing valuable insights and methods for the development of TCM for PF.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-01899-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pulmonary fibrosis</kwd><kwd>Huaxian formula</kwd><kwd>PI3K/AKT pathway</kwd><kwd>Network Pharmacology</kwd><kwd>Experimental validation</kwd><kwd>Nickel oxide nanoparticles</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Bioinformatics</kwd><kwd>Experimental organisms</kwd><kwd>Animal disease models</kwd><kwd>Respiratory tract diseases</kwd><kwd>Experimental models of disease</kwd></kwd-group><funding-group><award-group><funding-source><institution>College Students Training Program for Innovation and Entrepreneurship</institution></funding-source><award-id>S202310716092</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of Ningxia</institution></funding-source><award-id>2024AAC03225</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par26">Nanomaterials encompass a diverse range of ultrafine particles with sizes between 1 and 100&#x000a0;nm. These materials consist of nano-sized microcrystals, including metallic, non-metallic, organic, inorganic, and biological powders<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Notably, nanomaterials exhibit remarkable durability and chemical stability<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Nickel oxide nanoparticles (nano NiO), a type of nanometal oxide, are widely utilized in medical healthcare, scientific research, and various industrial applications<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. However, due to their unique physicochemical properties, nano NiO particles can penetrate deep into the alveoli and interstitial tissues, increasing the risk of pulmonary toxicity<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref></sup>. Animal studies have demonstrated that exposure to nano NiO is directly associated with the development of pulmonary fibrosis (PF). The underlying mechanism involves nano NiO-induced alveolar inflammation, which leads to collagen deposition and ultimately results in PF<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Our previous research has shown that nano NiO induces epithelial-mesenchymal transition and collagen deposition in A549 and BEAS-2B cells. This process involves TGF-&#x003b2;1-mediated activation of the PI3K/AKT and JNK/c-Jun signaling pathways<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par27">PF is a chronic progressive interstitial lung disease stimulated by continuous damage and excessive repair of alveolar epithelial cells<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. A recent meta-analysis hass identified PF as an independent risk factor for lung cancer, with both high mortality and incidence rates worldwide<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Currently, antifibrotic agents such as nintedanib and pirfenidone have demonstrated efficacy in slowing disease progression; however, they fail to achieve disease stabilization or reversal. Additionally, these drugs are linked to a high incidence of adverse effects, particularly gastrointestinal and hepatic toxicity, further limiting their clinical utility<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Consequently, there is an urgent demand for the development of novel, safe and more effective therapeutic agents.</p><p id="Par28">In Chinese medicine, PF is called &#x0201c;Feiwei&#x0201d;, mainly characterized by lung dryness-heat, lung qi deficiency, the consumption of body fluids, and involving blood stasis<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. The Hua-Xian Formula (HXF), designed to address the pathogenesis and symptoms of PF, consists of seven ingredients: <italic>Stephaniae tetrandrae radix</italic> (FJ), <italic>Rhizoma fagopyri cymosi</italic> (JQM), <italic>Platycladi cacumen</italic> (CB), <italic>Hedysarum Multijugum Maxim.</italic> (HQ), <italic>Platycodon grandiflorus</italic> (JG), <italic>Poria cocos (Schw.) Wolf.</italic> (FL) and <italic>Glycyrrhiza glabra L.</italic> (GC)<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. The therapeutic strategy of HXF aligns with core Chinese medicine doctrines in managing PF. HQ addresses the fundamental &#x0201c;intrinsic deficiency&#x0201d; by replenishing lung-spleen qi, thereby enhancing host defense mechanisms and tissue repair capacity<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. Concurrently, JG and JQM collaboratively clear heat-toxin, resolve phlegm, and eliminate dampness, targeting key pathological factors in PF<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. FG functions as a pulmonary decongestant by enhancing lymphatic drainage and capillary permeability, thereby reducing alveolar edema<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. CB serves as a vascular stabilizer and bronchial relaxant, addressing hemoptysis and persistent cough through its bioactive flavonoids<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. FL provides dual-modality support via aquaporin modulation for fluid homeostasis and immunomodulatory polysaccharides that reinforce the lung-spleen axis<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. GC serves dual roles as a harmonizer to potentiate herb interactions and as a guide drug to enhance pulmonary targeting, while providing adjunctive antitussive and anti-inflammatory benefits<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. This multi-target approach embodies the traditional Chinese medicine (TCM) principle of &#x0201c;simultaneous root-symptom treatment,&#x0201d; paralleling the mechanism of classical formula such as Buyang Huanwu Tang<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. When the seven components are combined, these ingredients work synergistically to moisturize the lungs, detoxify the body, invigorate the spleen and qi, and promote the circulation of qi and blood<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par29">Our previous research indicated that HXF could inhibit the elevation of Type 1 collagen protein (Col-I) content in rat lung tissues induced by nano NiO, through the TGF-&#x003b2;1/Smads pathway<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Additionally, studies have suggested that HXF could counteract silica induced PF by modulating the TGF-&#x003b2;1/Smads pathway<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. In clinical practice, HQ injection has demonstrated efficacy in treating patients with pulmonary tuberculosis and PF, potentially through the regulation of fibrosis-related factors and inflammatory cytokines<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. Wang et al.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. found that HQ injection can be clinically used to treat PF induced by pneumoconiosis due to its potent anti-fibrotic effects. JQM is utilized in treating asthmatic bronchitis in infants and young children, exhibiting anti-inflammatory properties, promoting absorption of inflammatory exudates, and facilitating tissue repair and regeneration<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Tetrandrine, an alkaloid extracted from FG, has been shown to improve lung function in patients with pneumoconiosis. Administered alongside acetylcysteine, it effectively reduces inflammatory factor levels, alleviates cough symptoms, enhances treatment efficacy, and decreases the incidence of complications<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Moreover, a mixture of FL and GC can improve lung function, inhibit oxidative stress and inflammatory reactions, delay muscle atrophy. Consequently, this herbal mixture is utilized in the clinical management of chronic obstructive pulmonary disease associated with muscle atrophy<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p><p id="Par30">Although previous studies have shown that HXF can ameliorate PF, its precise mechanism of action remains unclear. Due to uncertainties regarding their composition and targets, TCM formulas are currently controversial in clinical applications. Network pharmacology (NP), a discipline, studies pharmacological effects by integrating systems biology and pharmacology. It focuses on the systematic analysis of interactions among drugs, targets, and disease-related biological pathways, aiming to understand the overall mechanism of drug action and predict potential side effects<sup><xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref></sup>. This approach provides an advanced technological mean to reveal the overall mechanisms of TCM treating diseases<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. In addition, molecular docking analyses deliver crucial insights into the binding modes and stability of protein-drug complexes<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>.</p><p id="Par31">Accordingly, we employed several high-precision, authoritative databases to identify the potential active constituents of HXF. Key compounds were then screened to forecast the core targets by combining them with disease databases. Functional enrichment analysis was performed to predict the primary mechanisms through which HXF exerts its effects on PF. Additionally, molecular docking was utilized to elucidate the ligand-target interactions at the molecular level between the active compounds and the primary targets. Furthermore, the rat PF model was established using nano-NiO in vivo. Masson staining of lung tissue was applied to observe the collagen deposition. The outcome indicators of PF and key pathway proteins were assessed to explore the efficacy and mechanisms of HXF. Finally, we developed an A549 cell model to study collagen deposition in vitro, further validating HXF&#x02019;s therapeutic effects and underlying mechanisms in PF treatment. We were committed to determine the substance basis and mechanisms underlying the therapeutic potential of HXF. The content of our study was shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par32">
<fig id="Fig1"><label>Fig. 1</label><caption><p>The graphical abstract of this study. This figure was generated using multiple computational tools including Cytoscape (v3.9.1, <ext-link ext-link-type="uri" xlink:href="https://github.com/cytoscape/">https://github.com/cytoscape/</ext-link>), AutoDock Vina (v1.5.7, <ext-link ext-link-type="uri" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</ext-link>), LigPlot+ (v2.2.9, <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/">https://www.ebi.ac.uk/</ext-link>), PyMOL (v3.0.4, <ext-link ext-link-type="uri" xlink:href="https://pymol.org/">https://pymol.org/</ext-link>), and GraphPad Prism (v7.0, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>).</p></caption><graphic xlink:href="41598_2025_1899_Fig1_HTML" id="d33e600"/></fig>
</p><sec id="Sec1"><title>Results</title><sec id="Sec2"><title>The NP analyses</title><sec id="Sec3"><title>Screening of the bioactive components and targets of HXF</title><p id="Par33">According to ADME analysis, a total of 121 bioactive compounds from HXF were identified through the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, meeting the criteria of oral bioavailability (OB)&#x02009;&#x02265;&#x02009;30% and drug likeness (DL)&#x02009;&#x02265;&#x02009;0.18 (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>). These compounds collectively interact with 202 potential targets, forming 4468 connections, with an average node degree of 13.50. Among these, 66 nodes had degree values exceeding the average. B1 (quercetin) exhibited the highest target interactions, followed by I1 (luteolin) and A1 (kaempferol). The top 6 core components were listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, as well these structural formulas were listed in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Of the 202 targets, those with degree values above 70 include PTGS2 (120), ESR1 (87), AR (83), NCOA2 (77), NOS2 (77), and PTGS1 (76). The HXF-compound-target network was established by Cytoscape 3.9.1 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par34">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>The top 6 core components of HXF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">MOLID</th><th align="left">Compound</th><th align="left">Degree</th><th align="left">molecular weight (g/moL)</th><th align="left">CAS</th></tr></thead><tbody><tr><td align="left">MOL000098</td><td align="left">Quercetin</td><td char="." align="char">492</td><td char="." align="char">302.23</td><td char="&#x02212;" align="char">73123-10-1</td></tr><tr><td align="left">MOL000006</td><td align="left">Luteolin</td><td char="." align="char">154</td><td char="." align="char">286.24</td><td char="&#x02212;" align="char">491-70-3</td></tr><tr><td align="left">MOL000422</td><td align="left">Kaempferol</td><td char="." align="char">144</td><td char="." align="char">286.24</td><td char="&#x02212;" align="char">520-18-3</td></tr><tr><td align="left">MOL000358</td><td align="left">Beta-sitosterol</td><td char="." align="char">78</td><td char="." align="char">414.70</td><td char="&#x02212;" align="char">83-46-5</td></tr><tr><td align="left">MOL000354</td><td align="left">Isorhamnetin</td><td char="." align="char">63</td><td char="." align="char">316.26</td><td char="&#x02212;" align="char">480-19-3</td></tr><tr><td align="left">MOL000392</td><td align="left">Formononetin</td><td char="." align="char">50</td><td char="." align="char">268.26</td><td char="&#x02212;" align="char">485-72-3</td></tr></tbody></table></table-wrap>
</p><p id="Par35">
<fig id="Fig2"><label>Fig. 2</label><caption><p>The molecular structure of the top six core components of HXF.</p></caption><graphic xlink:href="41598_2025_1899_Fig2_HTML" id="d33e723"/></fig>
</p><p id="Par36">
<fig id="Fig3"><label>Fig. 3</label><caption><p>The active compound-targets of HXF. The hexagons represent the active compounds of herbs. The octagons on the right represent the shared components of herbs (A1: CB, GC and HQ; B1: CB, GC, HQ and JQM; C1: CB, FJ, GC and JQM; D1: FJ and HQ; E1, E2, H1, H2: GC and HQ; F1: GC, HQ and JQM; I1: JQM and JG).The blue quadrangles in the middle represent the targets. All edges represent the interaction between HXF and compounds or compounds and targets. This figure was generated using Cytoscape (v3.9.1, <ext-link ext-link-type="uri" xlink:href="https://github.com/cytoscape/">https://github.com/cytoscape/</ext-link>) and GraphPad Prism (v7.0, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>).</p></caption><graphic xlink:href="41598_2025_1899_Fig3_HTML" id="d33e742"/></fig>
</p></sec><sec id="Sec4"><title>Identification of shared targets and construction of the PPI network</title><p id="Par37">1664 PF targets were identified using authoritative databases. Among these, 105 targets overlapped with HXF, as shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A, and were used to construct a PPI network visualized in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B. The network consists of 105 nodes, 428 edges, with an average node degree of 8.15. Based on node degree, the top 20 key nodes were identified and are presented in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C. The top five nodes in terms of degree values are STAT3, MAPK3, RELA, MAPK1, and AKT1.</p><p id="Par38">
<fig id="Fig4"><label>Fig. 4</label><caption><p>The protein-protein interaction (PPI) network of HXF targets for the treatment of PF. (<bold>A</bold>) The common targets of HXF and PF by venny2.1.0. (<bold>B</bold>) The detailed common targets of HXF and PF. Darker color and larger circle represent higher degree value. All edges represent the core targets interaction. (<bold>C</bold>) Top 20 core targets.</p></caption><graphic xlink:href="41598_2025_1899_Fig4_HTML" id="d33e775"/></fig>
</p></sec><sec id="Sec5"><title>Exploration of target pathways through gene ontology (GO) and Kyoto Encyclopedia of genes and geneomes (KEGG) analyses</title><p id="Par39">To clarify the biological functions and signaling pathways of 105 overlapping genes GO and KEGG enrichment analyses were conducted. The GO biological processes (BP) include &#x0201c;response to lipopolysaccharide&#x0201d;, &#x0201c;positive regulation of cell migration&#x0201d;, &#x0201c;response to peptide&#x0201d;, etc. These are associated with immune response, cellular signaling, and environmental responses. For cellular component (CC), enriched terms include &#x0201c;extracellular matrix&#x0201d;, &#x0201c;plasma membrane part&#x0201d;, and &#x0201c;platelet alpha granule lumen&#x0201d;. These results highlight the significant involvement of structural and signaling elements, particularly those related to membrane-associated and extracellular regions. In the molecular function (MF) category, &#x0201c;cytokine receptor binding&#x0201d;, &#x0201c;transcription factor binding&#x0201d;, and &#x0201c;protein homodimerization activity&#x0201d; were enriched notablely. These functions are crucial for receptor-ligand interactions, transcriptional regulation, and PPI within cellular processes (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). In addition, the KEGG pathway analysis HXF acting on PF mainly involves cancer pathway, lipid and atherosclerosis, PI3K-AKT signaling pathway&#x0201d;, chemical carcinogenesis-receptor activation, TNF signaling pathway and other signaling pathways (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B).</p><p id="Par40">
<fig id="Fig5"><label>Fig. 5</label><caption><p>GO and KEGG enrichment analysis of 105 shared targets. (<bold>A</bold>) Go enrichment. (<bold>B</bold>) KEGG pathway analysis. Darker color and larger circle represent higher degree value. Large bubble represents the more genes involved, and redder bubble represents the more statistically significant. The red rectangular box on the left indicates that we will confirm it via subsequent experiments in this study. This figure was generated using KEGG (<ext-link ext-link-type="uri" xlink:href="https://www.kegg.jp/kegg/kegg1.html">https://www.kegg.jp/kegg/kegg1.html</ext-link>) and Wei Sheng Xin (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.com.cn/">http://www.bioinformatics.com.cn/</ext-link>).</p></caption><graphic xlink:href="41598_2025_1899_Fig5_HTML" id="d33e810"/></fig>
</p></sec></sec><sec id="Sec6"><title>Analysis of molecular docking results</title><p id="Par41">The six primary components of HXF&#x02014;quercetin, luteolin, kaempferol, beta-sitosterol, isorhamnetin, and formononetin&#x02014;were docked with protein molecules PI3K and AKT in the PI3K/AKT pathway. The binding energies, shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, were all below zero, indicating that each ligand can spontaneously bind to its receptor. A lower binding energy reflects a more stable binding conformation. In this study, all 12 ligand-receptor pairs exhibited binding energies well below zero, suggesting stable interactions between the compounds and their targets. As shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, the 3D and 2D docking results, visualized using PyMol, further illustrated these interactions. Notably, beta-sitosterol with AKT and formononetin with AKT did not display polar bonds, implying that their interactions may involve nonpolar forces instead (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>).</p><p id="Par42">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Binding energy values between the active compounds and the targets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Ligand component</th><th align="left">Receptor protein</th><th align="left">Binding energy (kcal/mol)</th></tr></thead><tbody><tr><td align="left">Quercetin</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;8.0</td></tr><tr><td align="left">Quercetin</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;8.0</td></tr><tr><td align="left">Luteolin</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;8.3</td></tr><tr><td align="left">Luteolin</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;8.1</td></tr><tr><td align="left">Kaempferol</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;8.4</td></tr><tr><td align="left">Kaempferol</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;7.7</td></tr><tr><td align="left">Beta&#x02212;&#x000a0;sitosterol</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;7.9</td></tr><tr><td align="left">Beta&#x02212;&#x000a0;sitosterol</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;7.9</td></tr><tr><td align="left">Isorhamnetin</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;8.0</td></tr><tr><td align="left">Isorhamnetin</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;8.4</td></tr><tr><td align="left">Formononetin</td><td align="left">PI3K</td><td char="." align="char">&#x02212;&#x000a0;7.7</td></tr><tr><td align="left">Formononetin</td><td align="left">AKT</td><td char="." align="char">&#x02212;&#x000a0;7.8</td></tr></tbody></table></table-wrap>
</p><p id="Par43">
<fig id="Fig6"><label>Fig. 6</label><caption><p>The 3D and 2D docking patterns and interactions of HXF with the targets in the PI3K/AKT signaling pathway. (<bold>A-J</bold>) The molecular docking quercetin with PI3K, quercetin with AKT, luteolin with PI3K, luteolin with AKT, kaempferol with PI3K, kaempferol with AKT, beta-sitosterol with PI3K, isorhamnetin with PI3K, isorhamnetin with AKT, and formononetin with AKT, respectively. The protein backbone is represented in light blue, amino acid residues interacting with ligands in pale green, and the drug molecules in light magenta. Yellow dashed lines indicate the distances between HXF components and amino acid residues in these 3D structures. This figure was generated using AutoDock Vina (v1.5.7, <ext-link ext-link-type="uri" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</ext-link>), LigPlot+ (v2.2.9, <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/">https://www.ebi.ac.uk/</ext-link>), PyMOL (v3.0.4, <ext-link ext-link-type="uri" xlink:href="https://pymol.org/">https://pymol.org/</ext-link>), and GraphPad Prism (v7.0, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>).</p></caption><graphic xlink:href="41598_2025_1899_Fig6_HTML" id="d33e959"/></fig>
</p></sec><sec id="Sec7"><title>Animal experiment verification</title><sec id="Sec8"><title>Alleviation of HXF on nano NiO-induced PF in rats</title><p id="Par44">The anti-PF effect of HXF was evaluated in rats treated with nano NiO. Masson staining was performed to assess pathological changes in the lung tissue. The control group exhibited clear lung tissue with no signs of fibrosis. In contrast, the nano NiO-treated group showed altered alveolar size, structural damage, and significant collagen fiber deposition around the alveoli. In the nano NiO&#x02009;+&#x02009;500&#x000a0;mg/kg HXF group, some alveoli appeared atrophic, and collagen fiber deposition was reduced, indicating an improvement in lung abnormalities induced by nano NiO. Notably, in the nano NiO&#x02009;+&#x02009;1000&#x000a0;mg/kg HXF group, the lung tissue structure was largely intact, with a substantial reduction in blue-stained collagen fibers, approaching a nearly normal appearance (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A<sub>1</sub>&#x02013;A<sub>4</sub> and B).</p><p id="Par45">To evaluate the protective effects of HXF against nano NiO-induced PF, we analyzed key PF biomarkers in rats, with a specific focus on Col-I protein levels. As shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C and D, Col-I protein expression was significantly higher in the nano NiO group compared to the control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). However, treatment with HXF at doses of 500&#x000a0;mg/kg and 1000&#x000a0;mg/kg resulted in a marked reduction in Col-I protein expression (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><p id="Par46">
<fig id="Fig7"><label>Fig. 7</label><caption><p>The HXF eased nano NiO-induced PF in the rats. (<bold>A</bold><sub><bold>1</bold></sub>&#x02013;<bold>A</bold><sub><bold>4</bold></sub>) Collagen deposition in the control group, nano NiO group, nano NiO&#x02009;+&#x02009;500&#x000a0;mg/kg HXF group, nano NiO&#x02009;+&#x02009;1000&#x000a0;mg/kg HXF group by Masson staining, respectively (<italic>n</italic>&#x02009;=&#x02009;3). (<bold>B</bold>) Semiquantitative analysis of collagen deposition. (<bold>C</bold>) Col-I protein bands. (<bold>D</bold>) Semiquantitative analysis of Col-I protein levels (<italic>n</italic>&#x02009;=&#x02009;5). Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD. * The nano NiO group versus the control group, # nano NiO&#x02009;+&#x02009;HXF groups versus the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="41598_2025_1899_Fig7_HTML" id="d33e1025"/></fig>
</p></sec><sec id="Sec9"><title>Regulation of HXF in PI3K/AKT signal pathway</title><p id="Par47">To confirm that HXF alleviates nano NiO-induced PF through the PI3K/AKT pathway, we examined the protein levels of PI3K, AKT, p-PI3K, and p-AKT. As illustrated in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>, the levels of p-PI3K, p-AKT, and their ratios (p-PI3K/PI3K and p-AKT/AKT) were significantly elevated in the nano NiO group compared to the control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). In contrast, treatment with 500 and 1000&#x000a0;mg/kg HXF resulted in a significant downregulation of p-PI3K, p-AKT, p-PI3K/PI3K, and p-AKT/AKT levels compared to the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Whereas, the protein expression levels of PI3K and AKT did not elicit any changes in each group (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><p id="Par48">
<fig id="Fig8"><label>Fig. 8</label><caption><p>HXF inhibited PI3K/AKT transduction in Nano NiO administrated rats (<italic>n</italic>&#x02009;=&#x02009;5). (<bold>A</bold>) Protein bands. (<bold>B-D</bold>) Semiquantitative analysis of protein levels. Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD. * The nano NiO group versus the control group, # nano NiO&#x02009;+&#x02009;HXF groups versus the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="41598_2025_1899_Fig8_HTML" id="d33e1064"/></fig>
</p></sec></sec><sec id="Sec10"><title>Cell experiment verification</title><sec id="Sec11"><title>Evaluation of cell viability</title><p id="Par49">To determine the optimal doses of HXF and PFD, A549 cells were treated with various concentrations of HXF (0, 50, 100, 200, 400&#x000a0;&#x000b5;g/mL) or pirfenidone (PFD; 0, 0.5, 1, 2, 4 mM) for 48&#x000a0;h. The results displayed a significant reduction in cell viability compared to the control group after treatment with 400&#x000a0;&#x000b5;g/mL HXF and 4 mM PFD (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; see Fig. <xref rid="MOESM2" ref-type="media">S2</xref> and Fig. S3). Based on the above results, cells were pretreated with nano NiO for 24&#x000a0;h and then treated with 50, 100, and 200&#x000a0;&#x000b5;g/mL HXF or 0.5, 1.0, and 2.0 mM PFD for 48&#x000a0;h. As depicted in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>, treatment with 100&#x000a0;&#x000b5;g/mL nano NiO resulted in significant cytotoxicity. However, 100&#x000a0;&#x000b5;g/mL HXF or 2 mM PFD effectively mitigated this toxicity. Therefore, these concentrations were selected for subsequent experiments.</p><p id="Par50">
<fig id="Fig9"><label>Fig. 9</label><caption><p>Cell viability in different treatment Groups in A549 cells (<italic>n</italic>&#x02009;=&#x02009;5). Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD. * The nano NiO group versus the control group, # nano NiO combined with drug groups versus the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="41598_2025_1899_Fig9_HTML" id="d33e1096"/></fig>
</p></sec><sec id="Sec12"><title>Effect of HXF on nano NiO-induced collagen formation in A549 cells</title><p id="Par51">To further validate the protective role of HXF against nano NiO-induced PF, we assessed Col-I protein expression in vitro. The results demonstrated that Col-I protein levels were markedly elevated in the nano NiO group than in the control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). In contrast, treatment with 100&#x000a0;&#x000b5;g/mL HXF and 2mM PFD significantly attenuated Col-I protein expression (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05;&#x000a0;Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>).</p><p id="Par52">
<fig id="Fig10"><label>Fig. 10</label><caption><p>The HXF lessened nano NiO-induced collagen deposition in A549 cells. (<bold>A</bold>) Col-I protein bands. (<bold>B</bold>) Semiquantitative analysis of Col-I protein levels (<italic>n</italic>&#x02009;=&#x02009;3). Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD. * The nano NiO group versus the control group, # nano NiO combined with drug groups versus the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="41598_2025_1899_Fig10_HTML" id="d33e1132"/></fig>
</p></sec><sec id="Sec13"><title>Involvement of HXF in PI3K/AKT pathway regulation</title><p id="Par53">The expression levels of key proteins in the PI3K/AKT pathway were further assessed in A549 cells. In the Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>, the levels of p-PI3K, AKT, p-AKT, and their respective ratios (p-PI3K/PI3K and p-AKT/AKT) were significantly higher in the nano NiO group compared to the control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Conversely, treatment with 100&#x000a0;&#x000b5;g/mL HXF notably lowered the levels of p-PI3K, AKT, p-AKT, and their ratios (p-PI3K/PI3K and p-AKT/AKT) compared to the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><p id="Par54">
<fig id="Fig11"><label>Fig. 11</label><caption><p>HXF suppressed PI3K/AKT signaling in A549 cells treated with Nano NiO (<italic>n</italic>&#x02009;=&#x02009;3). (A) Protein bands. (B-D) Semiquantitative analysis of protein levels. Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD. * The nano NiO group versus the control group, # nano NiO combined with drug groups versus the nano NiO group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="41598_2025_1899_Fig11_HTML" id="d33e1162"/></fig>
</p></sec></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par55">NiO Nanoparticles have attracted significant attention for their potential role in PF, a chronic, progressive lung disease involving excessive extracellular matrix deposition and fibrotic tissue formation<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. In TCM theory, PF is interpreted as an imbalance of qi, blood, and fluid dynamics in pulmonary tissues, ultimately leading to fibrotic transformation and potentially malignant progression. To address this pathogenesis, the HXF formula was strategically developed as a combination of qi-tonifying (HQ and GC), heat-clearing (JQM and CB), and phlegm-resolving (FJ, JG and FL) herbs, each selected based on centuries of empirical TCM practice<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Meanwhile, modern pharmacological studies have begun to validate this traditional knowledge by identifying specific bioactive components within HXF that mechanistically combat fibrosis. For instance, Astragaloside IV from HQ has been shown to modulate TGF-&#x003b2;1/Smad pathway in a silica-induced rat model of PF, while quercetin (found in CB, GC, HQ and JQM) exhibits potent anti-inflammatory property<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. This multi-herb formulation exemplifies the TCM principle of &#x0201c;synergistic multi-target therapy&#x0201d;, simultaneously addressing inflammation and fibroblast activation pathways implicated in nano NiO-induced PF. While preliminary studies have demonstrated the efficacy of HXF in alleviating PF via modulation of the TGF-&#x003b2;1/Smad pathway, the complete mechanistic understanding remains limited due to the inherent complexity of multi-component herbal formulations<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. The present study aims to bridge this gap by integrating NP, molecular docking, and experimental validation in both cellular and animal models, offering a comprehensive elucidation of HXF&#x02019;s anti-fibrotic mechanisms against nano NiO-triggered lung injury.</p><p id="Par56">NP, employing computer-based simulations and network database retrieval, is utilized to identify key pharmacodynamic ingredients and targets. In this study, 121 core compounds and 202 corresponding key targets of HXF were identified. Among these, quercetin exhibited the highest number of interactions, suggesting that quercetin may be the primary active constituent of HXF for treating PF caused by nano NiO. This finding aligned with research by Hohmann et al.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. which demonstrated that quercetin reverses bleomycin-induced PF and downregulates pulmonary senescence markers in aged mice. Moreover, in this study&#x02019;s PPI network, the top five degree-ranked common targets were STAT3, MAPK3, RELA, MAPK1, and AKT1. KEGG Pathway analysis showed significant enrichment in fibrosis-related pathways, with the PI3K/AKT signaling pathway emerging as one of the most prominent. GO (BP) analysis revealed that the common targets are primarily associated with responses to inorganic substances and exogenous stimuli, implicating their potential role in nano NiO-induced PF, with PI3K/AKT pathway-mediated cellular stress response. Furthermore, this pathway is related with regulating cell migration and apoptosis, processes that contribute to fibroblast persistence in fibrotic lesions. These findings underscore the potential central role of PI3K/AKT signaling in the therapeutic effects of HXF on PF.</p><p id="Par57">The PI3K/AKT pathway serves as a master regulator of multiple cellular functions through its phosphorylation cascade<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. PI3K catalyzes the transfer of G-phosphate from ATP to the D3 position of phosphatidylinositol, while AKT, a serine/threonine protein kinase, is activated in response to upstream PI3K. After activation, AKT signaling reaches various substrates with distinct functions<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Abnormal activity in this pathway is linked to multiple diseases, such as neurodegenerative diseases, stroke, diabetes, and cancer. Evidence indicates that overexpression of alpha-smooth muscle actin in lung fibrosis is associated with PI3K/AKT activation<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. A clinical study demonstrated that p-AKT was increased 3-fold in alveolar macrophages of idiopathic PF patients compared with normal tissues<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Additionally, in clinical practice, the PI3K/AKT signaling pathway has been considered as a master regulator for PF. Inhibitors targeting this pathway are currently undergoing clinical evaluation and hold promise for the development of novel anti-fibrotic strategies<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Therefore, this study selected the PI3K/AKT signaling pathway in animal experiments to further validate HXF&#x02019;s intervention effect on nano NiO-induced PF.</p><p id="Par58">To validate the interactions between identified compounds and predicted targets, molecular docking analysis was conducted. Results suggested stable binding between certain compounds and verified targets. Quercetin, luteolin, kaempferol, beta-sitosterol, isorhamnetin, and formononetin displayed significant affinity for PI3K/AKT pathway proteins, thus highlighting these compounds as essential constituents of HXF in treating PF. These computational findings are further supported by existing experimental evidence, as multiple studies have demonstrated that quercetin, luteolin, kaempferol, and isorhamnetin can alleviate PF by modulating the PI3K/AKT signaling pathway<sup><xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref></sup>. The strong consistency between our molecular docking results and previously reported pharmacological data supports the anti-fibrotic potential of HXF.</p><p id="Par59">In vivo experiments were performed to further explore potential mechanisms. Masson staining of lung tissue revealed that HXF treatment, especially at higher doses, effectively alleviated lung collagen deposition and alveolar shrinkage caused by nano NiO exposure. Collagen composition analysis from biopsy specimens of fibrotic patients revealed increased levels of Col-I and Col-III in early-stage fibrosis, whereas mature scar tissue predominantly consisted of Col-I<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Thus, Col-I was selected as an outcome indicator. Results showed nano NiO exposure led to increased Col-I protein levels, while HXF treatment significantly reduced Col-I, indicating that HXF can ameliorate nano NiO-induced PF. This finding aligned with Liu et al.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. which showed reduced collagen deposition in bleomycin-treated mice upon treatment with Qing-Xuan Granule. Notably, nano NiO significantly increased p-PI3K and p-AKT levels, while HXF inhibited their phosphorylation, suggesting that HXF may alleviate collagen overproduction by blocking the PI3K/AKT pathway. Interestingly, this mechanism is similar with the Jinshui Huanxian formula reported by Shao et al.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, which also targets PI3K/AKT signaling. Both formulas share GC and the bioactive compound isorhamnetin, indicating that these common components may underlie their anti-fibrotic effects and warrant further pharmacological investigation.</p><p id="Par60">To further elucidate the underlying mechanisms, we conducted in vitro experiments. Cytotoxicity assays revealed that 100&#x000a0;&#x000b5;g/mL of HXF effectively mitigated the cytotoxic effects induced by nano NiO. Moreover, HXF significantly reduced collagen deposition and modulated the aberrant expression of key proteins in the PI3K/AKT pathway. As a positive control, 2 mM pirfenidone (PFD) was used to validate the anti-pulmonary fibrosis (PF) efficacy of HXF. It is noteworthy that HXF exhibited therapeutic effects and mechanisms of action comparable to those of PFD. These findings align with in vivo data, further supporting that HXF (a TCM) effectively modulates key proteins implicated in PF. This underscores its potential as a natural therapeutic agent or adjunct for clinical PF management.</p></sec><sec id="Sec15"><title>Conclusions</title><p id="Par61">In this study, we investigated the therapeutic effects of HXF on nano NiO-induced PF and its underlying mechanisms by integrating NP prediction, molecular docking analysis, and experimental verification. Our results demonstrated that HXF could mitigate PF induced by nano NiO exposure. Quercetin, luteolin, kaempferol, beta-sitosterol, isorhamnetin, and formononetin were identified as the primary compounds in HXF responsible for this anti-fibrotic effect, acting through mechanisms associated with the PI3K/AKT signaling pathway. This study provided clues for potential clinical applications in treating PF.</p></sec><sec id="Sec16"><title>Materials and methods</title><sec id="Sec17"><title>Analysis of NP</title><sec id="Sec18"><title>Screening of active components and presumed targets of HXF</title><p id="Par62">The HXF comprises seven herbs: CB, FJ, FL, GC, HQ, JQM, and JG. To identify the primary bioactive components and their corresponding targets, we accessed the TCMSP database (<ext-link ext-link-type="uri" xlink:href="https://old.tcmsp-e.com/index.php">https://old.tcmsp-e.com/index.php</ext-link>). We filtered the bioactive compounds of HXF based on the following criteria: OB&#x02009;&#x02265;&#x02009;30% and DL&#x02009;&#x02265;&#x02009;0.18. Additionally, we collected related protein targets for these bioactive compounds. Then the identified targets were standardized using the UniProt database (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/">https://www.uniprot.org/</ext-link>). Finally, the Cytoscape3.9.1 was applied to construct the HXF-compound-target network.</p></sec><sec id="Sec19"><title>Gathering of PF-associated targets</title><p id="Par63">The related targets of PF from multiple databases, including GeneCards (<ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link>), Therapeutic Target Database (TTD; <ext-link ext-link-type="uri" xlink:href="http://db.idrblab.net/ttd/">http://db.idrblab.net/ttd/</ext-link>) and UniProt<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Besides, the common targets of HXF and PF were extracted via drawing Venn Diagram (<ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link>).</p></sec><sec id="Sec20"><title>PPI network analysis</title><p id="Par64">The common targets were uploaded to the online STRING database (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>) with species restricted to Homo sapiens and confidence scores set to &#x02265;&#x02009;0.9. Subsequently, the results were downloaded and utilized to generate the PPI network diagram using Cytoscape3.9.1. Eventually, the top 20 core nodes were identified based on their degree values and illustrated accordingly.</p></sec><sec id="Sec21"><title>Enrichment analysis</title><p id="Par65">To elucidate the gene functions and signaling pathways of HXF acting on PF, the common targets were submitted to the Metascape website (<ext-link ext-link-type="uri" xlink:href="https://metascape.org/">https://metascape.org/</ext-link>) for GO function and KEGG enrichment analyses (<ext-link ext-link-type="uri" xlink:href="https://www.kegg.jp/kegg/kegg1.html">https://www.kegg.jp/kegg/kegg1.html</ext-link>). And results were visualized by the Bioinformatics website (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.com.cn/">http://www.bioinformatics.com.cn/</ext-link>).</p></sec></sec><sec id="Sec22"><title>Molecular docking</title><p id="Par66">AutoDock Vina1.5.7 was employed to conduct molecular docking simulations, aiming to predict both the binding affinity and conformation of key active ingredients with core protein targets. The active ingredients were initially obtained in sdf format from PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) and converted to pdb format using Open Babel GUI. The 3D structure of each core protein was downloaded from the RCSB Protein Data Bank (PDB) (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>), with water molecules and ligands removed using PyMOL3.0.4<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. After that, Receptors (proteins) and ligands (active pharmaceutical ingredients) were imported into AutoDock Vina1.5.7 for docking. A grid box was configured, and the docking box was adjusted based on the molecular sizes. Docking outcomes were assessed through binding energy, with values &#x0003c; -4.5&#x000a0;kJ/mol indicating strong binding affinity between component and target<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Finally, PyMOL3.0.4 and LigPlot<sup>+</sup>2.2.9 were applied to visualize the docking results in 3D and 2D formats, respectively.</p></sec><sec id="Sec23"><title>Experimental study in vivo and in vitro</title><sec id="Sec24"><title>Chemicals and drugs</title><p id="Par67">Nano NiO particles were obtained from ST-nano science and technology Co., Ltd (Shanghai, China). The characterization of these particles has been detailed in our previous study<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. To ensure sterility, the nano NiO was treated at 120&#x000a0;&#x000b0;C for 30&#x000a0;min. The nano NiO suspension was then prepared using an ultrasonic homogenizer (Ningbo Scientz Biotechnology Co., Ltd, China).</p><p id="Par68">The formulation consists of seven herbal granules, obtained from the affiliated hospital of Shaanxi University of Chinese Medicine. These granules were produced by licensed pharmaceutical manufacturers using a concentrated drying method. The quality ratio of FJ, JQM, CB, HQ, JG, FL and GC is 2: 2: 2: 2: 2: 5: 1<sup>15,16,23</sup>. The specific information of each component was listed in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. HXF is transformed into granules through a series of processes, including grinding, extraction, concentration, and drying. This method can effectively extract the active ingredients from TCM formulas. Each step of the process conducts meticulous control of parameters to ensure the quality and efficacy of HXF.</p><p id="Par69">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Detailed information of herbs in HXF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Chinese name</th><th align="left">Latin name</th><th align="left">Abbreviation</th><th align="left">Part used</th><th align="left">Amount (g)</th><th align="left">Origin</th><th align="left">Batch number</th></tr></thead><tbody><tr><td align="left">Fangji</td><td align="left">
<italic>Stephaniae tetrandrae radix</italic>
</td><td align="left">FJ</td><td align="left">Roots</td><td align="left">15</td><td align="left">Jiangxi</td><td char="." align="char">19,070,002</td></tr><tr><td align="left">Jinqiaomai</td><td align="left">
<italic>Rhizoma fagopyri cymosi</italic>
</td><td align="left">JQM</td><td align="left">Rhizomes</td><td align="left">15</td><td align="left">Guizhou</td><td char="." align="char">19,070,161</td></tr><tr><td align="left">Cebai</td><td align="left">
<italic>Platycladi cacumen</italic>
</td><td align="left">CB</td><td align="left">Leave</td><td align="left">15</td><td align="left">Shandong</td><td char="." align="char">19,120,235</td></tr><tr><td align="left">Huangqi</td><td align="left">
<italic>Hedysarum Multijugum Maxim</italic>
</td><td align="left">HQ</td><td align="left">Roots</td><td align="left">15</td><td align="left">Gansu</td><td char="." align="char">20,060,146</td></tr><tr><td align="left">Jiegeng</td><td align="left">
<italic>Platycodon grandiflorus</italic>
</td><td align="left">JG</td><td align="left">Roots</td><td align="left">15</td><td align="left">Anhui</td><td char="." align="char">20,060,152</td></tr><tr><td align="left">Fuling</td><td align="left">
<italic>Poria cocos (Schw.) Wolf.</italic>
</td><td align="left">FL</td><td align="left">Sclerotium</td><td align="left">37.5</td><td align="left">Yunnan</td><td char="." align="char">21,010,116</td></tr><tr><td align="left">Gancao</td><td align="left">
<italic>Glycyrrhiza glabra L.</italic>
</td><td align="left">GC</td><td align="left">Roots rhizomes</td><td align="left">7.5</td><td align="left">Xinjiang</td><td char="." align="char">21,010,106</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec25"><title>Experimental animals</title><p id="Par70">Thirty male Sprague-Dawley rats, weighing 200&#x02013;220&#x000a0;g, were acquired from Chengdu Dossy Experimental Animals Co., Ltd (license: SCXK(Chuan)2020-030). The rats were housed in sterilized polypropylene cages with free access to food and water, under a 12-hour light/dark cycle at a temperature of 22&#x02013;24&#x000a0;&#x000b0;C. They were acclimatized for one week prior to the start of the experiment. During the twenty-eight-day experimental period, the rats were fed a standard experimental diet. All animal procedures were performed in strict compliance with the Guide for the Care and Use of Laboratory Animals. The experimental protocols were reviewed and approved by the Animal Ethics Committee of Shaanxi University of Chinese Medicine (Approval No.: SUCMDL20210320001). Furthermore, all animal experiments were conducted in accordance with the ARRIVE guidelines.</p></sec><sec id="Sec26"><title>Cell culture</title><p id="Par71">A549 cells were provided by the Cancer Research Institute of Xi&#x02019;an Jiaotong University (Shaanxi, China). The cells were cultured in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibodies (100 units/mL of penicillin and 100&#x000a0;&#x000b5;g/mL of streptomycin), and were maintained at 37&#x000a0;&#x000b0;C in a humidified atmosphere containing 5% CO&#x02082;.</p></sec><sec id="Sec27"><title>Study design</title><p id="Par72">Rats were randomly divided into four groups: control, nano NiO, low-dose HXF, and high-dose HXF. The control group received intratracheal administration of physiological saline (0.9% NaCl), while rats in the other groups were administered a single intratracheal instillation of 1 mL nano NiO suspension (50&#x000a0;mg/mL) to induce lung fibrosis. Before the tracheal instillation procedure, the rats were anesthetized with an intraperitoneal injection of 50&#x000a0;mg/kg sodium pentobarbital. The following day, rats in the low-dose and high-dose HXF groups were orally gavaged with 500&#x000a0;mg/kg and 1000&#x000a0;mg/kg of HXF, respectively<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Rats in the control and nano NiO groups received distilled water instead. After 28 days of continuous treatment, the rats were anesthetized with 50&#x000a0;mg/kg sodium pentobarbital and euthanized by decapitation once fully anesthetized. Their lung tissues were then harvested for further analysis.</p><p id="Par73">A549 cells underwent treatment with varying concentrations of HXF (0, 50, 100, 200, 400&#x000a0;&#x000b5;g/mL) or PFD (0, 0.5, 1, 2, 4 mM; TargetMol Chemicals Inc., Shanghai, China) for 48&#x000a0;h to perform CCK-8 assay<sup><xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>. HXF or PFD was dissolved in DMSO (Beijing Solarbio Science &#x00026; Technology Co., Ltd, China), with the final concentration of DMSO in the solution being 0.1%. According to these preliminary results, cells were pretreated with 100&#x000a0;&#x000b5;g/mL nano NiO for 24 hours<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, followed by treatment with 50, 100, and 200&#x000a0;&#x000b5;g/mL HXF or 0.5, 1.0, and 2.0 mM PFD for an additional 48&#x000a0;h to assess cell viability. From these findings, 100&#x000a0;&#x000b5;g/mL HXF and 2.0 mM PFD were selected for further analysis of the protein expression levels of Col-I, PI3K, AKT, p-PI3K, and p-AKT.</p></sec><sec id="Sec28"><title>Histopathological examination</title><p id="Par74">Three rats were randomly selected from each group, and the frontal lobes of the right lung were fixed in 4% paraformaldehyde at room temperature and embedded in paraffin. The tissues were sectioned into 4&#x000a0;&#x003bc;m slices and stained with Masson&#x02019;s trichrome. These sections were then scanned using the SQS-40R Slide Scanning System (40X; Shengqiang Technology Co., Ltd, China). Randomly selected 3 regions from each slide and performed quantitative analysis on collagen content (blue staining) by ImageJ and visualize it using GraphPad Prism 7.0. Collagen deposition area (%)&#x02009;=&#x02009;Blue staining area / Total view area &#x000d7; 100%.</p></sec><sec id="Sec29"><title>CCK-8 assay</title><p id="Par75">Cell viability was measured via the CCK-8 Cell Proliferation Detection Kit (TargetMol Chemicals Inc., Shanghai, China) in triplicate. A549 cells were seeded into 96-well plates at a density of 5000 cells per well and incubated. Following incubation, 10 &#x000b5;L of CCK-8 reagent was added to each well, and the plates were incubated at 37&#x000a0;&#x000b0;C for 1&#x02013;4&#x000a0;h in the incubator. The absorbance of each well was then assessed at 450&#x000a0;nm using a microplate reader (KAIAO technology, China).</p></sec><sec id="Sec30"><title>Western blot</title><p id="Par76">The 80&#x000a0;mg middle lobes of right lung tissues were collected from each rat to assess protein content. The tissue samples were homogenized in lysis buffer containing 800 &#x000b5;L RIPA, 8 &#x000b5;L PMSF and 8 &#x000b5;L Phosphatase Inhibitor. Total protein levels were determined using a protein assay kit (Boster Biological Technology Co. Ltd., China). Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% skim milk for 4&#x000a0;h at room temperature, followed by overnight incubation at 4&#x000a0;&#x000b0;C with primary antibodies at a 1:500 dilution. Primary antibodies included &#x003b2;-actin (Signalway Antibody, USA), Col-I, PI3K, p-PI3K, AKT, and p-AKT (Immunoway, USA). After membranes were incubated with goat anti-rabbit secondary antibodies (1:5000 dilution) for 2&#x000a0;h. Protein detection was performed using an enhanced chemiluminescence system (Thermo Fisher Scientific, USA) and visualized on a Molecular Imager ChemiDoc XRS System (Bio-Rad, USA). Quantitative analysis of protein bands was conducted using IPP software (Media Cybernetics Inc., China), with protein expression normalized to &#x003b2;-actin.</p></sec><sec id="Sec31"><title>Statistical analysis</title><p id="Par77">The data analysis was performed using SPSS26.0 and the results were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD). The groups were compared by one-way ANOVA. Post-hoc comparisons were performed using LSD if variances were equal; otherwise, Dunnett&#x02019;s T3 was applied. A p-value less than 0.05 was considered statistically significant.</p></sec></sec></sec><sec id="Sec33" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2025_1899_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41598_2025_1899_MOESM2_ESM.docx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HXF</term><def><p id="Par3">Huaxian formula</p></def></def-item><def-item><term>TCM</term><def><p id="Par4">Traditional Chinese Medicine</p></def></def-item><def-item><term>PF</term><def><p id="Par5">Pulmonary fibrosis</p></def></def-item><def-item><term>nano NiO</term><def><p id="Par6">Nickel oxide nanoparticles</p></def></def-item><def-item><term>NP</term><def><p id="Par7">Network pharmacology</p></def></def-item><def-item><term>TCMSP</term><def><p id="Par8">Traditional Chinese Medicine Systems Pharmacology </p></def></def-item><def-item><term>TTD</term><def><p id="Par9">Therapeutic target database</p></def></def-item><def-item><term>PPI</term><def><p id="Par10">Protein&#x02013;protein interaction</p></def></def-item><def-item><term>GO</term><def><p id="Par11">Gene ontology</p></def></def-item><def-item><term>KEGG</term><def><p id="Par12">Kyoto encyclopedia of genes and genomes</p></def></def-item><def-item><term>Col-I</term><def><p id="Par13">Type I collagen</p></def></def-item><def-item><term>FJ</term><def><p id="Par14">
<italic>Stephaniae tetrandrae radix</italic>
</p></def></def-item><def-item><term>JQM</term><def><p id="Par15">
<italic>Rhizoma fagopyri cymosi</italic>
</p></def></def-item><def-item><term>CB</term><def><p id="Par16">
<italic>Platycladi cacumen</italic>
</p></def></def-item><def-item><term>HQ</term><def><p id="Par17">
<italic>Hedysarum Multijugum Maxim.</italic>
</p></def></def-item><def-item><term>JG</term><def><p id="Par18">
<italic>Platycodon grandiflorus</italic>
</p></def></def-item><def-item><term>FL</term><def><p id="Par19">
<italic>Poria cocos (Schw.) Wolf</italic>
</p></def></def-item><def-item><term>GC</term><def><p id="Par20">
<italic>Glycyrrhiza glabra L.</italic>
</p></def></def-item><def-item><term>OB</term><def><p id="Par200">Oral bioavailability</p></def></def-item><def-item><term>DL</term><def><p id="Par21">Drug likeness</p></def></def-item><def-item><term>ADME</term><def><p id="Par22">Absorption, distribution, metabolism, and excretion</p></def></def-item><def-item><term>PDB</term><def><p id="Par23">RCSB protein data bank</p></def></def-item><def-item><term>SD</term><def><p id="Par24">Standard deviation</p></def></def-item><def-item><term>PFD</term><def><p id="Par25">Pirfenidone</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, M.M.T., L.H. and G.L.; Investigation, M.M.T., L.F., M.T., X.M., S.B., J.L., J.X. and Y.X.; Methodology: M.M.T., L.F., M.T., X.M., S.B., J.L.; Visualization, M.M.T.; Data curation, M.M.T.; Validation, M.M.T., M.T.; Writing-original draft, M.M.T.; Funding acquisition, L.F., L.H. and G.L.; Project administration, L.H. and G.L.; Writing-review &#x00026; editing, G.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The research was funded by the College Students Training Program for Innovation and Entrepreneurship (No. S202310716092), the Natural Science Foundation of Ningxia (No. 2024AAC03225).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par79">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>The effects of nano-SiO<sub>2</sub> and nano-TiO<sub>2</sub> addition on the durability and deterioration of concrete subject to freezing and thawing cycles</article-title><source>Mater. (Basel)</source><year>2019</year><volume>12</volume><fpage>3608</fpage><lpage>3618</lpage><pub-id pub-id-type="doi">10.3390/ma12213608</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Liu, F. et al. The effects of nano-SiO<sub>2</sub> and nano-TiO<sub>2</sub> addition on the durability and deterioration of concrete subject to freezing and thawing cycles. <italic>Mater. (Basel)</italic>. <bold>12</bold>, 3608&#x02013;3618. 10.3390/ma12213608 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>G</given-names></name><etal/></person-group><article-title>High-performance NiO/TiO<sub>2</sub>/ZnO photovoltaic UV detector</article-title><source>Sens. (Basel)</source><year>2023</year><volume>23</volume><fpage>2741</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.3390/s23052741</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Shang, G. et al. High-performance NiO/TiO<sub>2</sub>/ZnO photovoltaic UV detector. <italic>Sens. (Basel)</italic>. <bold>23</bold>, 2741&#x02013;2747. 10.3390/s23052741 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Sana</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Biogenesis and application of nickel nanoparticles: A review</article-title><source>Curr. Pharm. Biotechnol.</source><year>2021</year><volume>22</volume><fpage>808</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.2174/1389201022999210101235233</pub-id><pub-id pub-id-type="pmid">33397255</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sana, S. S. et al. Biogenesis and application of nickel nanoparticles: A review. <italic>Curr. Pharm. Biotechnol.</italic><bold>22</bold>, 808&#x02013;822. 10.2174/1389201022999210101235233 (2021).<pub-id pub-id-type="pmid">33397255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Pietruska</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Bioavailability, intracellular mobilization of nickel, and HIF-1&#x003b1; activation in human lung epithelial cells exposed to metallic nickel and nickel oxide nanoparticles</article-title><source>Toxicol. Sci.</source><year>2011</year><volume>124</volume><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfr206</pub-id><pub-id pub-id-type="pmid">21828359</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Pietruska, J. R. et al. Bioavailability, intracellular mobilization of nickel, and HIF-1&#x003b1; activation in human lung epithelial cells exposed to metallic nickel and nickel oxide nanoparticles. <italic>Toxicol. Sci.</italic><bold>124</bold>, 138&#x02013;148. 10.1093/toxsci/kfr206 (2011).<pub-id pub-id-type="pmid">21828359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of oxidative stress and inflammatory response in subchronic pulmonary toxicity induced by nano nickel oxide in rats</article-title><source>J. Nanosci. Nanotechnol</source><year>2017</year><volume>17</volume><fpage>1753</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1166/jnn.2017.12849</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Zhu, A. et al. Role of oxidative stress and inflammatory response in subchronic pulmonary toxicity induced by nano nickel oxide in rats. <italic>J. Nanosci. Nanotechnol</italic>. <bold>17</bold>, 1753&#x02013;1761. 10.1166/jnn.2017.12849 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of acute oxidative stress on rat lung induced by nano and fine-scale, soluble and insoluble metal oxide particles: NiO and TiO<sub>2</sub></article-title><source>Inhal Toxicol.</source><year>2012</year><volume>24</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.3109/08958378.2012.682321</pub-id><pub-id pub-id-type="pmid">22642288</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Horie, M. et al. Comparison of acute oxidative stress on rat lung induced by nano and fine-scale, soluble and insoluble metal oxide particles: NiO and TiO<sub>2</sub>. <italic>Inhal Toxicol.</italic><bold>24</bold>, 391&#x02013;400. 10.3109/08958378.2012.682321 (2012).<pub-id pub-id-type="pmid">22642288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>The pulmonary effects of nickel-containing nanoparticles: cytotoxicity, genotoxicity, carcinogenicity, and their underlying mechanisms</article-title><source>Environ. Sci. Nano</source><year>2024</year><volume>11</volume><fpage>1817</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1039/d3en00929g</pub-id><pub-id pub-id-type="pmid">38984270</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mo, Y., Zhang, Y. &#x00026; Zhang, Q. The pulmonary effects of nickel-containing nanoparticles: cytotoxicity, genotoxicity, carcinogenicity, and their underlying mechanisms. <italic>Environ. Sci. Nano</italic>. <bold>11</bold>, 1817&#x02013;1846. 10.1039/d3en00929g (2024).<pub-id pub-id-type="pmid">38984270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>H</given-names></name><etal/></person-group><article-title>LncRNA MEG3 involved in NiO NPs-induced pulmonary fibrosis via regulating TGF-&#x003b2;1-mediated PI3K/AKT pathway</article-title><source>Toxicol. Sci.</source><year>2021</year><volume>182</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfab047</pub-id><pub-id pub-id-type="pmid">33895847</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zhan, H. et al. LncRNA MEG3 involved in NiO NPs-induced pulmonary fibrosis via regulating TGF-&#x003b2;1-mediated PI3K/AKT pathway. <italic>Toxicol. Sci.</italic><bold>182</bold>, 120&#x02013;131. 10.1093/toxsci/kfab047 (2021).<pub-id pub-id-type="pmid">33895847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>LncRNA HOTAIRM1 involved in nano NiO-induced pulmonary fibrosis via regulating PRKCB DNA Methylation-mediated JNK/c-Jun pathway</article-title><source>Toxicol. Sci.</source><year>2022</year><volume>190</volume><fpage>64</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfac092</pub-id><pub-id pub-id-type="pmid">36066426</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zheng, J. et al. LncRNA HOTAIRM1 involved in nano NiO-induced pulmonary fibrosis via regulating PRKCB DNA Methylation-mediated JNK/c-Jun pathway. <italic>Toxicol. Sci.</italic><bold>190</bold>, 64&#x02013;78. 10.1093/toxsci/kfac092 (2022).<pub-id pub-id-type="pmid">36066426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Chinese medicine as a therapeutic option for pulmonary fibrosis: clinical efficacies and underlying mechanisms</article-title><source>J. Ethnopharmacol.</source><year>2024</year><volume>318</volume><fpage>116836</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2023.116836</pub-id><pub-id pub-id-type="pmid">37406748</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hao, Y. et al. Chinese medicine as a therapeutic option for pulmonary fibrosis: clinical efficacies and underlying mechanisms. <italic>J. Ethnopharmacol.</italic><bold>318</bold>, 116836. 10.1016/j.jep.2023.116836 (2024).<pub-id pub-id-type="pmid">37406748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Krabbe</surname><given-names>J</given-names></name><name><surname>Steffens</surname><given-names>KM</given-names></name><name><surname>Drie&#x000df;en</surname><given-names>S</given-names></name><name><surname>Kraus</surname><given-names>T</given-names></name></person-group><article-title>Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis</article-title><source>Eur. Respir Rev.</source><year>2024</year><volume>33</volume><fpage>230224</fpage><pub-id pub-id-type="doi">10.1183/16000617.0224-2023</pub-id><pub-id pub-id-type="pmid">38355151</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Krabbe, J., Steffens, K. M., Drie&#x000df;en, S. &#x00026; Kraus, T. Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis. <italic>Eur. Respir Rev.</italic><bold>33</bold>, 230224. 10.1183/16000617.0224-2023 (2024).<pub-id pub-id-type="pmid">38355151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline</article-title><source>Am. J. Respir Crit. Care Med.</source><year>2022</year><volume>205</volume><fpage>18</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1164/rccm.202202-0399ST</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. <italic>Am. J. Respir Crit. Care Med.</italic><bold>205</bold>, 18&#x02013;47. 10.1164/rccm.202202-0399ST (2022).</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Nintedanib in progressive fibrosing interstitial lung diseases</article-title><source>N Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1908681</pub-id><pub-id pub-id-type="pmid">31566307</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. <italic>N Engl. J. Med.</italic><bold>381</bold>, 1718&#x02013;1727. 10.1056/NEJMoa1908681 (2019).<pub-id pub-id-type="pmid">31566307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential</article-title><source>Biomed. Pharmacother</source><year>2021</year><volume>133</volume><fpage>111072</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.111072</pub-id><pub-id pub-id-type="pmid">33378971</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang, Y. et al. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential. <italic>Biomed. Pharmacother</italic>. <bold>133</bold>, 111072. 10.1016/j.biopha.2020.111072 (2021).<pub-id pub-id-type="pmid">33378971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name></person-group><article-title>Regulatory effect of Chinese herbal compound on TGF-&#x003b2;1/Smads in lung tissues of rats exposed to silica dusts</article-title><source>Chin. J. Ind. Med.</source><year>2019</year><volume>32</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.13631/j.cnki.zggyyx.2019.03.005</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Guo, J., Zhang, J., Yu, G., Zhang, Z. &#x00026; Shao, H. Regulatory effect of Chinese herbal compound on TGF-&#x003b2;1/Smads in lung tissues of rats exposed to silica dusts. <italic>Chin. J. Ind. Med.</italic><bold>32</bold>, 180&#x02013;185. 10.13631/j.cnki.zggyyx.2019.03.005 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Guo, J. Regulatory effect of self-made traditional Chinese medicine and pirfenidone on TGF-&#x003b2;1/Smad signaling pathway in rat early stage of silicosis. <italic>Master&#x02019;s Thesis</italic> (2019). <ext-link ext-link-type="uri" xlink:href="http://www.cnki.net">http://www.cnki.net</ext-link></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Integrating network analysis and experimental validation to reveal the mitophagy-associated mechanism of Yiqi Huoxue (yqhx) prescription in the treatment of myocardial ischemia/reperfusion injury</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>189</volume><fpage>106682</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106682</pub-id><pub-id pub-id-type="pmid">36736970</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Chen, M. et al. Integrating network analysis and experimental validation to reveal the mitophagy-associated mechanism of Yiqi Huoxue (yqhx) prescription in the treatment of myocardial ischemia/reperfusion injury. <italic>Pharmacol. Res.</italic><bold>189</bold>, 106682. 10.1016/j.phrs.2023.106682 (2023).<pub-id pub-id-type="pmid">36736970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Exploring the role and mechanism of Astragalus Membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network Pharmacology and experimental validation</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>10110</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-36944-1</pub-id><pub-id pub-id-type="pmid">37666859</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jiang, H. et al. Exploring the role and mechanism of Astragalus Membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network Pharmacology and experimental validation. <italic>Sci. Rep.</italic><bold>13</bold>, 10110. 10.1038/s41598-023-36944-1 (2023).<pub-id pub-id-type="pmid">37666859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name></person-group><article-title>Platycodon grandiflorum (jacq.) A. Dc.: A review of phytochemistry, pharmacology, toxicology A.d traditional use</article-title><source>Phytomedicine</source><year>2022</year><volume>106</volume><fpage>154422</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2022.154422</pub-id><pub-id pub-id-type="pmid">36087526</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhang, S., Chai, X., Hou, G., Zhao, F. &#x00026; Meng, Q. Platycodon grandiflorum (jacq.) A. Dc.: A review of phytochemistry, pharmacology, toxicology A.d traditional use. <italic>Phytomedicine</italic><bold>106</bold>, 154422. 10.1016/j.phymed.2022.154422 (2022).<pub-id pub-id-type="pmid">36087526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>History of uses, phytochemistry, Pharmacological activities, quality control and toxicity of the root of S.ephania Tetrandra S. Moore: A review</article-title><source>J. Ethnopharmacol.</source><year>2020</year><volume>260</volume><fpage>112995</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2020.112995</pub-id><pub-id pub-id-type="pmid">32497674</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zhang, Y. et al. History of uses, phytochemistry, Pharmacological activities, quality control and toxicity of the root of S.ephania Tetrandra S. Moore: A review. <italic>J. Ethnopharmacol.</italic><bold>260</bold>, 112995. 10.1016/j.jep.2020.112995 (2020).<pub-id pub-id-type="pmid">32497674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A network Pharmacology approach and experimental validation to investigate the anticancer mechanism of Qi-Qin-Hu-Chang formula against colitis-associated colorectal cancer through induction of apoptosis via JNK/p38 MAPK signaling pathway</article-title><source>J. Ethnopharmacol.</source><year>2024</year><volume>319</volume><fpage>117323</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2023.117323</pub-id><pub-id pub-id-type="pmid">37852337</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wu, Y. et al. A network Pharmacology approach and experimental validation to investigate the anticancer mechanism of Qi-Qin-Hu-Chang formula against colitis-associated colorectal cancer through induction of apoptosis via JNK/p38 MAPK signaling pathway. <italic>J. Ethnopharmacol.</italic><bold>319</bold>, 117323. 10.1016/j.jep.2023.117323 (2024).<pub-id pub-id-type="pmid">37852337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>X</given-names></name><etal/></person-group><article-title>BuyangHuanwu Decoction alleviates endothelial cell apoptosis and coronary microvascular dysfunction via regulation of the MAPKK4/p38 signaling axis</article-title><source>Int. J. Med. Sci.</source><year>2024</year><volume>21</volume><fpage>2464</fpage><lpage>2479</lpage><pub-id pub-id-type="doi">10.7150/ijms.98183</pub-id><pub-id pub-id-type="pmid">39439466</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chang, X. et al. BuyangHuanwu Decoction alleviates endothelial cell apoptosis and coronary microvascular dysfunction via regulation of the MAPKK4/p38 signaling axis. <italic>Int. J. Med. Sci.</italic><bold>21</bold>, 2464&#x02013;2479. 10.7150/ijms.98183 (2024).<pub-id pub-id-type="pmid">39439466</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>M</given-names></name><etal/></person-group><article-title>The intervention effect of Huaxian formula on pulmonary fibrosis induced by nano NiO based on TGF-&#x003b2;1/Smads pathway</article-title><source>J. Toxicol.</source><year>2023</year><volume>37</volume><fpage>478</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.16421/j.cnki.1002-3127.2023.06.011</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tian, M. et al. The intervention effect of Huaxian formula on pulmonary fibrosis induced by nano NiO based on TGF-&#x003b2;1/Smads pathway. <italic>J. Toxicol.</italic><bold>37</bold>, 478&#x02013;483. 10.16421/j.cnki.1002-3127.2023.06.011 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>J</given-names></name></person-group><article-title>Influence of Huangqi injection on fibrosis indexes and cytokines of patient with pulmonary tuberculosis</article-title><source>J. Hainan Med. Univ.</source><year>2016</year><volume>22</volume><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.13210/j.cnki.jhmu.20150918.015</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Xi, J. Influence of Huangqi injection on fibrosis indexes and cytokines of patient with pulmonary tuberculosis. <italic>J. Hainan Med. Univ.</italic><bold>22</bold>, 138&#x02013;143. 10.13210/j.cnki.jhmu.20150918.015 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>Clinical efficacy of nebulized Budesonide combined with intravenous astragalus injection in treating idiopathic pulmonary fibrosis</article-title><source>Chin. J. Mod. Drug Appl.</source><year>2012</year><volume>6</volume><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.14164/j.cnki.cn11-5581/r.2012.23.075</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Liu, G. Clinical efficacy of nebulized Budesonide combined with intravenous astragalus injection in treating idiopathic pulmonary fibrosis. <italic>Chin. J. Mod. Drug Appl.</italic><bold>6</bold>, 44&#x02013;45. 10.14164/j.cnki.cn11-5581/r.2012.23.075 (2012).</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Effect of Astragalus injection on malondialdehyde and superoxide SOD to pneumoconiosis patients</article-title><source>J. Liaoning Univ. TCM</source><year>2010</year><volume>12</volume><fpage>105</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.13194/j.jlunivtcm.2010.12.107.wangzj.080</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang, Z. &#x00026; Yu, H. Effect of Astragalus injection on malondialdehyde and superoxide SOD to pneumoconiosis patients. <italic>J. Liaoning Univ. TCM</italic>. <bold>12</bold>, 105&#x02013;106. 10.13194/j.jlunivtcm.2010.12.107.wangzj.080 (2010).</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name></person-group><article-title>Clinical observation of Fagopyrum dibotrys tablets as adjuvant therapy for infantile asthmatic bronchitis</article-title><source>J. Bethune Military Med. Coll.</source><year>2010</year><volume>8</volume><fpage>34</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.16485/j.issn.2095-7858.2010.01.035</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wang, H., Yang, Y., Liu, S., Ge, L. &#x00026; Feng, Y. Clinical observation of Fagopyrum dibotrys tablets as adjuvant therapy for infantile asthmatic bronchitis. <italic>J. Bethune Military Med. Coll.</italic><bold>8</bold>, 34&#x02013;35. 10.16485/j.issn.2095-7858.2010.01.035 (2010).</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Clinical efficacy of Hanfangjisu tablets combined with acetylcysteine granules in the treatment of pneumoconiosis</article-title><source>China J. Pharmacol. Econ.</source><year>2025</year><volume>20</volume><fpage>81</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.12010/j.issn.1673-5846.2025.01.016</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dai, P. &#x00026; Liu, Y. Clinical efficacy of Hanfangjisu tablets combined with acetylcysteine granules in the treatment of pneumoconiosis. <italic>China J. Pharmacol. Econ.</italic><bold>20</bold>, 81&#x02013;83. 10.12010/j.issn.1673-5846.2025.01.016 (2025).</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Clinical efficacy of fuling Gancao mixture for chronic obstructive pulmonary disease with muscle Attenuation</article-title><source>Heibei J. TCM</source><year>2024</year><volume>46</volume><fpage>1436</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1002-2619.2024.09.007</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhang, W., Yu, H., Liu, X. &#x00026; Zhang, J. Clinical efficacy of fuling Gancao mixture for chronic obstructive pulmonary disease with muscle Attenuation. <italic>Heibei J. TCM</italic>. <bold>46</bold>, 1436&#x02013;1440. 10.3969/j.issn.1002-2619.2024.09.007 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Exploring the mechanism of Jinlida granules against type 2 diabetes mellitus by an integrative Pharmacology strategy</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>10286</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-61011-8</pub-id><pub-id pub-id-type="pmid">38704482</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Gu, H. et al. Exploring the mechanism of Jinlida granules against type 2 diabetes mellitus by an integrative Pharmacology strategy. <italic>Sci. Rep.</italic><bold>14</bold>, 10286. 10.1038/s41598-024-61011-8 (2024).<pub-id pub-id-type="pmid">38704482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Exploring the potential mechanisms of Danshen against COVID-19 via network Pharmacology analysis and molecular Docking</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>12780</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-62363-x</pub-id><pub-id pub-id-type="pmid">38834599</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang, Q., Liang, Z., Wang, X., Zhang, S. &#x00026; Yang, Z. Exploring the potential mechanisms of Danshen against COVID-19 via network Pharmacology analysis and molecular Docking. <italic>Sci. Rep.</italic><bold>14</bold>, 12780. 10.1038/s41598-024-62363-x (2024).<pub-id pub-id-type="pmid">38834599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>C</given-names></name><etal/></person-group><article-title>Network pharmacology: curing causal mechanisms instead of treating symptoms</article-title><source>Trends Pharmacol. Sci.</source><year>2022</year><volume>43</volume><fpage>136</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2021.11.004</pub-id><pub-id pub-id-type="pmid">34895945</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Nogales, C. et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. <italic>Trends Pharmacol. Sci.</italic><bold>43</bold>, 136&#x02013;150. 10.1016/j.tips.2021.11.004 (2022).<pub-id pub-id-type="pmid">34895945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Rajadnya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Novel systems biology experimental pipeline reveals Matairesinol&#x02019;s antimetastatic potential in prostate cancer: an integrated approach of network pharmacology, bioinformatics, and experimental validation</article-title><source>Brief. Bioinform</source><year>2024</year><volume>25</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/bib/bbae466</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Rajadnya, R. et al. Novel systems biology experimental pipeline reveals Matairesinol&#x02019;s antimetastatic potential in prostate cancer: an integrated approach of network pharmacology, bioinformatics, and experimental validation. <italic>Brief. Bioinform</italic>. <bold>25</bold>, 1&#x02013;24. 10.1093/bib/bbae466 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Zong</surname><given-names>Q</given-names></name><name><surname>Ling</surname><given-names>G</given-names></name></person-group><article-title>Application of molecular Docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin</article-title><source>Carbohydr. Polym.</source><year>2022</year><volume>276</volume><fpage>118644</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2021.118644</pub-id><pub-id pub-id-type="pmid">34823758</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Li, T., Guo, R., Zong, Q. &#x00026; Ling, G. Application of molecular Docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin. <italic>Carbohydr. Polym.</italic><bold>276</bold>, 118644. 10.1016/j.carbpol.2021.118644 (2022).<pub-id pub-id-type="pmid">34823758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>QD</given-names></name><etal/></person-group><article-title>Network Pharmacology and molecular Docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent Covid-19</article-title><source>Cell. Prolif.</source><year>2020</year><volume>53</volume><fpage>e12949</fpage><pub-id pub-id-type="doi">10.1111/cpr.12949</pub-id><pub-id pub-id-type="pmid">33140889</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Xia, Q. D. et al. Network Pharmacology and molecular Docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent Covid-19. <italic>Cell. Prolif.</italic><bold>53</bold>, e12949. 10.1111/cpr.12949 (2020).<pub-id pub-id-type="pmid">33140889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><etal/></person-group><article-title>Astragaloside IV alleviates silica-induced pulmonary fibrosis via inactivation of the TGF&#x02013;&#x003b2;1/Smad2/3 signaling pathway</article-title><source>Int. J. Mol. Med.</source><year>2021</year><volume>47</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2021.4849</pub-id><pub-id pub-id-type="pmid">33448318</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Li, N. et al. Astragaloside IV alleviates silica-induced pulmonary fibrosis via inactivation of the TGF&#x02013;&#x003b2;1/Smad2/3 signaling pathway. <italic>Int. J. Mol. Med.</italic><bold>47</bold>, 16&#x02013;25. 10.3892/ijmm.2021.4849 (2021).<pub-id pub-id-type="pmid">33448318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Quercetin, inflammation and immunity</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><fpage>167</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.3390/nu8030167</pub-id><pub-id pub-id-type="pmid">26999194</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Li, Y. et al. Quercetin, inflammation and immunity. <italic>Nutrients</italic><bold>8</bold>, 167&#x02013;180. 10.3390/nu8030167 (2016).<pub-id pub-id-type="pmid">26999194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Hohmann</surname><given-names>MS</given-names></name><name><surname>Habiel</surname><given-names>DM</given-names></name><name><surname>Coelho</surname><given-names>AL</given-names></name><name><surname>Verri</surname><given-names>WA</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name></person-group><article-title>Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis in vivo</article-title><source>Am. J. Respir Cell. Mol. Biol.</source><year>2019</year><volume>60</volume><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2017-0289OC</pub-id><pub-id pub-id-type="pmid">30109946</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hohmann, M. S., Habiel, D. M., Coelho, A. L., Verri, W. A. &#x00026; Hogaboam, C. M. Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis in vivo. <italic>Am. J. Respir Cell. Mol. Biol.</italic><bold>60</bold>, 28&#x02013;40. 10.1165/rcmb.2017-0289OC (2019).<pub-id pub-id-type="pmid">30109946</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name></person-group><article-title>The PI3K/AKT pathway in obesity and type 2 diabetes</article-title><source>Int. J. Biol. Sci.</source><year>2018</year><volume>14</volume><fpage>1483</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.7150/ijbs.27173</pub-id><pub-id pub-id-type="pmid">30263000</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Huang, X., Liu, G., Guo, J. &#x00026; Su, Z. The PI3K/AKT pathway in obesity and type 2 diabetes. <italic>Int. J. Biol. Sci.</italic><bold>14</bold>, 1483&#x02013;1496. 10.7150/ijbs.27173 (2018).<pub-id pub-id-type="pmid">30263000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>C</given-names></name><etal/></person-group><article-title>The PI3K/AKT pathway-the potential key mechanisms of traditional Chinese medicine for stroke</article-title><source>Front. Med. (Lausanne)</source><year>2022</year><volume>9</volume><fpage>900809</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.900809</pub-id><pub-id pub-id-type="pmid">35712089</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Gu, C. et al. The PI3K/AKT pathway-the potential key mechanisms of traditional Chinese medicine for stroke. <italic>Front. Med. (Lausanne)</italic>. <bold>9</bold>, 900809. 10.3389/fmed.2022.900809 (2022).<pub-id pub-id-type="pmid">35712089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis</article-title><source>Acta Pharm. Sin B</source><year>2022</year><volume>12</volume><fpage>18</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.07.023</pub-id><pub-id pub-id-type="pmid">35127370</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Wang, J. et al. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. <italic>Acta Pharm. Sin B</italic>. <bold>12</bold>, 18&#x02013;32. 10.1016/j.apsb.2021.07.023 (2022).<pub-id pub-id-type="pmid">35127370</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Larson-Casey</surname><given-names>JL</given-names></name><name><surname>Deshane</surname><given-names>JS</given-names></name><name><surname>Ryan</surname><given-names>AJ</given-names></name><name><surname>Thannickal</surname><given-names>VJ</given-names></name><name><surname>Carter</surname><given-names>AB</given-names></name></person-group><article-title>Macrophage Akt1 kinase-mediated mitophagy modulates apoptosis resistance and pulmonary fibrosis</article-title><source>Immunity</source><year>2016</year><volume>44</volume><fpage>582</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.001</pub-id><pub-id pub-id-type="pmid">26921108</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Larson-Casey, J. L., Deshane, J. S., Ryan, A. J., Thannickal, V. J. &#x00026; Carter, A. B. Macrophage Akt1 kinase-mediated mitophagy modulates apoptosis resistance and pulmonary fibrosis. <italic>Immunity</italic><bold>44</bold>, 582&#x02013;596. 10.1016/j.immuni.2016.01.001 (2016).<pub-id pub-id-type="pmid">26921108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Quercetin influences intestinal dysbacteriosis and delays alveolar epithelial cell senescence by regulating PTEN/PI3K/AKT signaling in pulmonary fibrosis</article-title><source>Naunyn Schmiedebergs Arch. Pharmacol.</source><year>2024</year><volume>397</volume><fpage>4809</fpage><lpage>4822</lpage><pub-id pub-id-type="doi">10.1007/s00210-023-02913-8</pub-id><pub-id pub-id-type="pmid">38153514</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wu, W. et al. Quercetin influences intestinal dysbacteriosis and delays alveolar epithelial cell senescence by regulating PTEN/PI3K/AKT signaling in pulmonary fibrosis. <italic>Naunyn Schmiedebergs Arch. Pharmacol.</italic><bold>397</bold>, 4809&#x02013;4822. 10.1007/s00210-023-02913-8 (2024).<pub-id pub-id-type="pmid">38153514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J</given-names></name><etal/></person-group><article-title>Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases</article-title><source>Front. Pharmacol.</source><year>2025</year><volume>16</volume><fpage>1535555</fpage><pub-id pub-id-type="doi">10.3389/fphar.2025.1535555</pub-id><pub-id pub-id-type="pmid">40012626</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lv, J. et al. Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases. <italic>Front. Pharmacol.</italic><bold>16</bold>, 1535555. 10.3389/fphar.2025.1535555 (2025).<pub-id pub-id-type="pmid">40012626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Modeling Kaempferol as a potential Pharmacological agent for COVID-19/PF co-occurrence based on bioinformatics and system Pharmacological tools</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>865097</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.865097</pub-id><pub-id pub-id-type="pmid">35754492</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Jiang, Y. et al. Modeling Kaempferol as a potential Pharmacological agent for COVID-19/PF co-occurrence based on bioinformatics and system Pharmacological tools. <italic>Front. Pharmacol.</italic><bold>13</bold>, 865097. 10.3389/fphar.2022.865097 (2022).<pub-id pub-id-type="pmid">35754492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Therapeutic effects and molecular mechanisms of bioactive compounds against respiratory diseases: traditional Chinese medicine theory and high-frequency use</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><fpage>734450</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.734450</pub-id><pub-id pub-id-type="pmid">34512360</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Wang, J. et al. Therapeutic effects and molecular mechanisms of bioactive compounds against respiratory diseases: traditional Chinese medicine theory and high-frequency use. <italic>Front. Pharmacol.</italic><bold>12</bold>, 734450. 10.3389/fphar.2021.734450 (2021).<pub-id pub-id-type="pmid">34512360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Activation of TGF-&#x003b2;1/&#x003b1;-SMA/Col-I profibrotic pathway in fibroblasts by Galectin-3 contributes to atrial fibrosis in experimental models and patients</article-title><source>Cell. Physiol. Biochem.</source><year>2018</year><volume>47</volume><fpage>851</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1159/000490077</pub-id><pub-id pub-id-type="pmid">29807358</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Shen, H. et al. Activation of TGF-&#x003b2;1/&#x003b1;-SMA/Col-I profibrotic pathway in fibroblasts by Galectin-3 contributes to atrial fibrosis in experimental models and patients. <italic>Cell. Physiol. Biochem.</italic><bold>47</bold>, 851&#x02013;863. 10.1159/000490077 (2018).<pub-id pub-id-type="pmid">29807358</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Protective effect of the traditional Chinese patent medicine Qing-xuan granule against bleomycin-induced pulmonary fibrosis in mice</article-title><source>Chem. Biodivers.</source><year>2019</year><volume>16</volume><fpage>e1900467</fpage><pub-id pub-id-type="doi">10.1002/cbdv.201900467</pub-id><pub-id pub-id-type="pmid">31556199</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Liu, B. et al. Protective effect of the traditional Chinese patent medicine Qing-xuan granule against bleomycin-induced pulmonary fibrosis in mice. <italic>Chem. Biodivers.</italic><bold>16</bold>, e1900467. 10.1002/cbdv.201900467 (2019).<pub-id pub-id-type="pmid">31556199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network Pharmacology</article-title><source>Phytomedicine</source><year>2022</year><volume>102</volume><fpage>154177</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2022.154177</pub-id><pub-id pub-id-type="pmid">35636171</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Shao, D. et al. Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network Pharmacology. <italic>Phytomedicine</italic><bold>102</bold>, 154177. 10.1016/j.phymed.2022.154177 (2022).<pub-id pub-id-type="pmid">35636171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Network Pharmacology and transcriptomics to explore the Pharmacological mechanisms of 20(s)-protopanaxatriol in the treatment of depression</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><fpage>7574</fpage><lpage>7593</lpage><pub-id pub-id-type="doi">10.3390/ijms25147574</pub-id><pub-id pub-id-type="pmid">39062817</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Guo, X. et al. Network Pharmacology and transcriptomics to explore the Pharmacological mechanisms of 20(s)-protopanaxatriol in the treatment of depression. <italic>Int. J. Mol. Sci.</italic><bold>25</bold>, 7574&#x02013;7593. 10.3390/ijms25147574 (2024).<pub-id pub-id-type="pmid">39062817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>Integrated multispectroscopic analysis and molecular Docking analyses of the structure-affinity relationship and mechanism of the interaction of flavonoids with Zein</article-title><source>Food Chem.</source><year>2022</year><volume>386</volume><fpage>132839</fpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2022.132839</pub-id><pub-id pub-id-type="pmid">35366631</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Li, R., Huang, L., Zhang, Z., Chen, J. &#x00026; Tang, H. Integrated multispectroscopic analysis and molecular Docking analyses of the structure-affinity relationship and mechanism of the interaction of flavonoids with Zein. <italic>Food Chem.</italic><bold>386</bold>, 132839. 10.1016/j.foodchem.2022.132839 (2022).<pub-id pub-id-type="pmid">35366631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Network Pharmacology and experimental validation-based approach to understand the effect and mechanism of Taohong Siwu Decoction against ischemic stroke</article-title><source>J. Ethnopharmacol.</source><year>2022</year><volume>294</volume><fpage>115339</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2022.115339</pub-id><pub-id pub-id-type="pmid">35525530</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pan, L. et al. Network Pharmacology and experimental validation-based approach to understand the effect and mechanism of Taohong Siwu Decoction against ischemic stroke. <italic>J. Ethnopharmacol.</italic><bold>294</bold>, 115339. 10.1016/j.jep.2022.115339 (2022).<pub-id pub-id-type="pmid">35525530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Nano NiO induced liver toxicity via activating the nf-&#x003ba;b signaling pathway in rats</article-title><source>Toxicol. Res. (Camb)</source><year>2017</year><volume>6</volume><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1039/c6tx00444j</pub-id><pub-id pub-id-type="pmid">30090495</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Liu, F. et al. Nano NiO induced liver toxicity via activating the nf-&#x003ba;b signaling pathway in rats. <italic>Toxicol. Res. (Camb)</italic>. <bold>6</bold>, 242&#x02013;250. 10.1039/c6tx00444j (2017).<pub-id pub-id-type="pmid">30090495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Astragaloside IV modulates TGF-&#x003b2;1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis</article-title><source>J. Cell. Mol. Med.</source><year>2018</year><volume>22</volume><fpage>4354</fpage><lpage>4365</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13725</pub-id><pub-id pub-id-type="pmid">29971947</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Qian, W., Cai, X., Qian, Q., Zhang, W. &#x00026; Wang, D. Astragaloside IV modulates TGF-&#x003b2;1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. <italic>J. Cell. Mol. Med.</italic><bold>22</bold>, 4354&#x02013;4365. 10.1111/jcmm.13725 (2018).<pub-id pub-id-type="pmid">29971947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Kurimoto</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pirfenidone May revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma</article-title><source>Oncol. Lett.</source><year>2017</year><volume>14</volume><fpage>944</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6188</pub-id><pub-id pub-id-type="pmid">28693256</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kurimoto, R. et al. Pirfenidone May revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. <italic>Oncol. Lett.</italic><bold>14</bold>, 944&#x02013;950. 10.3892/ol.2017.6188 (2017).<pub-id pub-id-type="pmid">28693256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>M</given-names></name><etal/></person-group><article-title>TGF-&#x003b2;1 mediated MAPK signaling pathway promotes collagen formation induced by nano NiO in A549 cells</article-title><source>Environ. Toxicol.</source><year>2019</year><volume>34</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1002/tox.22738</pub-id><pub-id pub-id-type="pmid">30810263</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Tian, M. et al. TGF-&#x003b2;1 mediated MAPK signaling pathway promotes collagen formation induced by nano NiO in A549 cells. <italic>Environ. Toxicol.</italic><bold>34</bold>, 719&#x02013;727. 10.1002/tox.22738 (2019).<pub-id pub-id-type="pmid">30810263</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>